By employing heterologous expression in the human embryonic kidney (HEK) 293T cells, we also explored the therapeutic potential of correcting leukodystrophy-associated anomalous human ClC-2 proteostasis by modulating chaperone/co-chaperone activity. Here, CLCN2 is linked to leukodystrophy.